SEP 30·SEC EDGARLow
Plott Ronald Todd purchased $10K of PHIO
Plott Ronald Todd purchased 10,000 shares of Phio Pharmaceuticals Corp. (PHIO) at an average of $1.04 ($1.03–$1.04) across 2 trades over 2026-09-28 to 2026-09-29.
StockNASDAQ · US · USDHealthcare · Biotechnology
$PHIO
Phio Pharmaceuticals Corp.
Price · $PHIOvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $PHIO in the last 7 days.
Insider · 30dAll trades →
- Buys
- $31K 5 txs
- Sells
- — 0 txs
BRADFORD PATRICIA A2× · $19K
10b5-1 share of filings0%
Top stories · $PHIOMore →
SEP 28·SEC EDGAR 8-K
Phio Pharmaceuticals Corp. (PHIO): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Phio Pharmaceuticals Corp. (PHIO) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Phio Pharmaceuticals Corp. (the “Company”) held its 2026 Annual Meeting of Stockholders via live webcast (the “Annual Meet
SEP 25·SEC EDGAR
BRADFORD PATRICIA A purchased $7K of PHIO
BRADFORD PATRICIA A purchased 6,500 shares of Phio Pharmaceuticals Corp. (PHIO) at $1.01 on 2026-09-24.
PHIO sentiment & insider activity
Recent PHIO coverage spans insider activity, corporate actions and technology.
In the last 30 days, PHIO insiders filed 5 SEC Form 4 transactions — 5 purchases ($31K) and no sales. The most active reporter was BRADFORD PATRICIA A with 2 filings.
What's driving PHIO
A modest insider purchase by a director signals confidence but the amount is small relative to market cap.
The increase in authorized shares may dilute existing shareholders and could support future equity compensation or financing.
Insider purchase signals confidence from a board member, modestly bullish.
Small insider buy by the CEO.
Small insider buy signals confidence but limited material impact.
AlphAI scores every news story that mentions PHIO with an AI model for sentiment and relevance, and aggregates insider trades from Phio Pharmaceuticals Corp.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $PHIO
Score
Plott Ronald Todd purchased $10K of PHIO
Plott Ronald Todd purchased 10,000 shares of Phio Pharmaceuticals Corp. (PHIO) at an average of $1.04 ($1.03–$1.04) across 2 trades over 2026-09-28 to 2026-09-29.
1 min readPhio Pharmaceuticals Corp. (PHIO): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Phio Pharmaceuticals Corp. (PHIO) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Phio Pharmaceuticals Corp. (the “Company”) held its 2026 Annual Meeting of Stockholders via live webcast (the “Annual Meet
1 min readBRADFORD PATRICIA A purchased $7K of PHIO
BRADFORD PATRICIA A purchased 6,500 shares of Phio Pharmaceuticals Corp. (PHIO) at $1.01 on 2026-09-24.
1 min readBitterman Robert J purchased $2K of PHIO
Bitterman Robert J (Chairman, Pres. & CEO) purchased 2,000 shares of Phio Pharmaceuticals Corp. (PHIO) at $1.03 on 2026-09-22.
1 min readBRADFORD PATRICIA A purchased $12K of PHIO
BRADFORD PATRICIA A purchased 12,000 shares of Phio Pharmaceuticals Corp. (PHIO) at $1.03 on 2026-09-15.
1 min read
Phio Announces Key Development Milestone for PH-762 with FDA Submission Supporting Next Stage of Clinical Development in Cutaneous Squamous Cell Carcinoma
Phio Pharmaceuticals (PHIO) submitted a meeting request and briefing package to the FDA for PH-762, its lead clinical compound for cutaneous squamous cell carcinoma. The submission follows the completion of a Phase 1b trial and outlines plans for a Phase 2b study. The company expects to complete final activities for the next clinical phase by Q1 2027.
2 min readPhio Announces Key Development Milestone for PH-762 with FDA Submission Supporting Next Stage of Clinical Development in Cutaneous Squamous Cell Carcinoma
Phio Pharmaceuticals Corp. (PHIO) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Phio Announces Key Development Milestone for PH-762 with FDA Submission Supporting Next Stage of Clinical Development in Cutaneous Squamous Cell Carcinoma Company Proposes Planned Phase 2b Neoadjuvant Study Following Successful Completion of Phase 1b Trial KING OF PR
1 min readPlott Ronald Todd purchased $17K of PHIO
Plott Ronald Todd purchased 15,000 shares of Phio Pharmaceuticals Corp. (PHIO) at $1.14 on 2026-08-19.
1 min readBitterman Robert J purchased $11K of PHIO
Bitterman Robert J (Chairman, Pres. & CEO) purchased 10,000 shares of Phio Pharmaceuticals Corp. (PHIO) at $1.06 on 2026-08-18.
1 min readPhio Pharmaceuticals Corp.: Phio Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update
Phio Pharmaceuticals (NASDAQ: PHIO) reported Q2 2026 results for the quarter ended June 30, 2026 and updated its PH-762 siRNA program. Cash fell to $13.0M from $21.0M at Dec. 31, 2025. R&D rose to $3.1M and net loss widened to $4.1M. PH-762 Phase 1b (22 patients) completed in March; FDA documentation is being prepared and an FDA meeting is planned for Q3 2026. The company also launched a $6.36M ATM equity program.
7 min read